Efficacy and safety of moclobemide compared with imipramine in the treatment of major depressive disorder. Double-blind Multicenter Study, Austria

Amine Oxidases and Their Impact on Neurobiology ◽

10.1007/978-3-7091-9113-2_26 ◽

1990 ◽

pp. 177-184 ◽

Author(s):

G. F. Hebenstreit ◽

M. Loidl ◽

U. Baumhackl ◽

B. Gallhofer ◽

Ch. Geretsegger ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Multicenter Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Download Full-text

Statement of Retraction: Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study

International Journal of Psychiatry in Clinical Practice ◽

10.1080/13651501.2021.1950437 ◽

2021 ◽

pp. 1-1

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

P.1.030 Double-blind, placebo-controlled,multicenter study evaluating nemifitide, a new pentapeptide antidepressant, when given daily or every other day for three weeks in the treatment of major depressive disorder

European Neuropsychopharmacology ◽

10.1016/s0924-977x(05)80258-5 ◽

2005 ◽

Vol 15 ◽

pp. S119

Author(s):

J.P. Feighner ◽

L. Sverdlov ◽

J. Hlavka ◽

G. Nicolau ◽

G. Tonelli ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Multicenter Study ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder

International Clinical Psychopharmacology ◽

10.1097/yic.0000000000000304 ◽

2020 ◽

Vol 35 (3) ◽

pp. 137-146 ◽

Author(s):

Andrea Fagiolini ◽

Umberto Albert ◽

Laura Ferrando ◽

Erik Herman ◽

Cosmina Muntean ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Extended Release ◽

Blind Study ◽

Double Blind Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Download Full-text

Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study

International Journal of Psychiatry in Clinical Practice ◽

10.1080/13651501.2017.1397700 ◽

2017 ◽

Vol 23 (4) ◽

pp. 245-250 ◽

Author(s):

Jing Wang ◽

Xi-Fang Liu ◽

Chong Feng ◽

Quan Bao ◽

Hong-Ran Fu

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

International Clinical Psychopharmacology ◽

10.1097/yic.0b013e3283542457 ◽

2012 ◽

Vol 27 (4) ◽

pp. 215-223 ◽

Author(s):

Cornelius Katona ◽

Thomas Hansen ◽

Christina Kurre Olsen

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Elderly Patients ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial

Yearbook of Psychiatry and Applied Mental Health ◽

10.1016/s0084-3970(08)79213-2 ◽

2009 ◽

Vol 2009 ◽

pp. 281-282

Author(s):

J.C. Ballenger

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial☆

Pain ◽

10.1016/j.pain.2008.02.024 ◽

2008 ◽

Vol 136 (3) ◽

pp. 432-444 ◽

Author(s):

Jon I. Russell ◽

Philip J. Mease ◽

Timothy R. Smith ◽

Daniel K. Kajdasz ◽

Madelaine M. Wohlreich ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Efficacy and safety of agomelatine oral administration (25 to 50 mg/day) in elderly patients suffering from major depressive disorder: an 8-week, randomised, double-blind, flexible-dose, parallel groups, placebo-controlled, international, multicentre study followed by an extension double-blind treatment period of 16 weeks

http://isrctn.org/> ◽

10.1186/isrctn57507360 ◽

2013 ◽

Author(s):

Reinhard Heun

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Elderly Patients ◽

Oral Administration ◽

Multicentre Study ◽

Treatment Period ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Download Full-text

Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Pharmacopsychiatry ◽

10.1055/s-2007-991684 ◽

2007 ◽

Vol 40 (05) ◽

Author(s):

M Ebrecht ◽

T Sickmann ◽

M Kungel ◽

C Werner ◽

R Marcus ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Adjunctive Therapy ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial

Journal of Affective Disorders ◽

10.1016/j.jad.2019.07.023 ◽

2019 ◽

Vol 257 ◽

pp. 143-149 ◽

Author(s):

Yifeng Shen ◽

Qian Zhao ◽

Yimin Yu ◽

Yunlong Tan ◽

Honggeng Zhang ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Extended Release ◽

Chinese Patients ◽

Efficacy And Safety ◽

Major Depressive ◽

Download Full-text